Clinical Research Directory
Browse clinical research sites, groups, and studies.
Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator
Sponsor: University of South Florida
Summary
The goal of this study is to learn whether adults who visit a hospital emergency department (ED) find it acceptable to start HIV pre-exposure prophylaxis (PrEP) during that same visit, with help from a peer navigator. PrEP is a daily pill that lowers the chance of getting HIV. Many people who could benefit from PrEP use the ED for health care but have no regular doctor, so they may never be offered it. The main questions this study aims to answer are: * Do participants find starting PrEP in the ED acceptable? * How many participants take the first dose, connect with an ongoing PrEP provider, and keep taking PrEP over one year? At Tampa General Hospital, a peer PrEP navigator (a trained study team member) will offer PrEP information to adults in the ED. Adults who agree to join the study and test HIV-negative will: * take their first PrEP pill in the ED while the navigator watches, and leave with a 29-day supply at no cost * choose a community PrEP provider for ongoing care, with help from the navigator * answer short surveys before leaving the ED and by phone at 2-3 days, 30 days, 60 days, 90 days, and 1 year * allow the navigator to confirm follow-up PrEP lab work with their outside provider at about 120 days
Official title: RAPID Response (Revolutionary Access to PrEP In the ED): A Pilot Implementation Study of Peer Navigator-Facilitated, Same-Visit Initiation of Oral HIV Pre-Exposure Prophylaxis in the Emergency Department
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-11
Completion Date
2028-05
Last Updated
2026-10-28
Healthy Volunteers
Yes
Interventions
RAPID Response peer navigation
A trained peer navigator identifies interested adults, coordinates HIV testing and the PrEP order, obtains the medication from the hospital outpatient pharmacy, observes the first dose, arranges a warm handoff to a community PrEP provider chosen by the participant, and contacts the participant during follow-up.
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
One 200 mg/300 mg tablet by mouth once daily, prescribed per FDA labeling. 30-day supply paid for by the study: first dose taken in the ED plus 29 tablets to take home.
Locations (1)
Tampa General Hospital
Tampa, Florida, United States